Rare Diseases Content
Optimizing outcomes of JAK inhibition in myelofibrosis: Practical considerations for the clinic
Two haematologic oncologists discuss optimizing the use of JAK inhibitors for patients with myelofibrosis.
- Discuss considerations for selecting an appropriate JAK inhibitor in the first-line treatment of myelofibrosis
- Plan strategies for managing side effects associated with JAK inhibition in patients with myelofibrosis
- Evaluate management approaches following lack of treatment success with first-line JAK inhibitor treatment in patients with myelofibrosis
Journal articles and more to your inbox
Get the latest clinical insights from touchHAEMATOLOGYSign me up!